155
Participants
Start Date
August 31, 2009
Primary Completion Date
August 31, 2010
Study Completion Date
February 28, 2011
ITCA 650
ITCA 650 (continuous delivery of exenatide in DUROS)
Exenatide Injection
twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
Ex Inj/ITCA 650
twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
Study Site, New Hyde Park
Study Site, Norfolk
Study Site, Charlotte
Study Site, Hickory
Study Site, Sandy Springs
Study Site, Atlanta
Study Site, Miramar
Study Site, Pembroke Pines
Study Site, Miami
Study Site, Miami
Study Site, Miami
Study Site, St. Petersburg
Study Site, Bradenton
Study Site, Lexington
Study Site, Franklin
Study Site, Cincinnati
Study Site, Cincinnati
Study Site, Kettering
Study Site, Avon
Study Site, Troy
Study Site, Ypsilanti
Study Site, Kalamazoo
Study Site, Traverse City
Study Site, Minneapolis
Study Site, Rapid City
Study Site, Chicago
Study Site, Wichita
Study Site, New Orleans
Study Site, Norman
Study Site, Irving
Study Site, Dallas
Study Site, Dallas
Study Site, San Antonio
Study Site, San Antonio
Study Site, Austin
Study Site, Austin
Study Site, Longmont
Study Site, Pueblo
Study Site, Meridian
Study Site, West Jordan
Study Site, Las Vegas
Study Site, Valley Village
Study Site, Chino
Study Site, National City
Study Site, La Jolla
Study Site, San Diego
Study Site, Sacramento
Study Site, Eugene
Study Site, Olympia
Study Site, Spokane
Lead Sponsor
Intarcia Therapeutics
INDUSTRY